Nikhil Lalwani is CEO & President at ANI PHARMACEUTICALS INC (ANIP). They have made 7 open-market trades across 1 company since 2022, most recently 2026-10-15.
CIK 0001822629
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $400K since 2022, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ANIP | 333,689 | $24.1M |
Shares reported on the most recent Form 4, priced at the 2026-10-16 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ANIP | SELL · 10b5-1 | 2026-10-15 | 2026-10-16 | $71.89 | $388K | — | — | — |
| ANIP | SELL · 10b5-1 | 2026-09-15 | 2026-09-16 | $71.00 | $383K | +1.4% | -2.1% | — |
| ANIP | SELL · 10b5-1 | 2026-08-25 | 2026-08-26 | $74.30 | $401K | -4.7% | +0.4% | — |
| ANIP | SELL | 2026-05-11 | 2026-05-13 | $77.57 | $4.3M | -0.3% | -0.0% | -8.5% |
| ANIP | SELL | 2025-08-12 | 2025-08-14 | $85.93 | $9.8M | +3.9% | +11.7% | -1.4% |
| ANIP | SELL | 2024-11-26 | 2024-11-27 | $58.02 | $2.1M | -0.3% | -8.3% | -8.1% |
| ANIP | SELL | 2024-05-14 | 2024-05-16 | $66.10 | $2.2M | -1.2% | -3.3% | -7.3% |
| ANIP | SELL | 2024-03-06 | 2024-03-08 | $66.10 | $6.0M | +2.9% | +2.1% | +3.9% |
| ANIP | SELL | 2023-08-11 | 2023-08-15 | $58.33 | $8.0M | +3.6% | +3.2% | -16.2% |
| ANIP | BUY | 2022-03-21 | 2022-03-23 | $27.69 | $400K | +6.1% | +17.4% | -9.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.